Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
H. Lundbeck A/S
Headquarters: Copenhagen, Denmark
Website: https://www.lundbeck.com/glob...
Year Founded: 1915
Status: Public
Industry Sector: HealthTechnology
CEO: Charl van Zyl, MBA
Number Of Employees: 5,707
Enterprise Value: $7,439,811,098
PE Ratio: 11.59
Exchange/Ticker 1: CSE:HLUN B
Exchange/Ticker 2: N/A
Latest Market Cap: $5,262,411,710
BioCentury | Mar 17, 2025
Product Development
Lundbeck’s next chapter: from psychiatry to rare neuro
Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more
BioCentury | Feb 28, 2025
Product Development
Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline
As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
BioCentury | Feb 28, 2025
Management Tracks
Indivior CEO exits as activist shareholder Oaktree presses for change
Plus: Paul Hitchin succeeds Laetitia Rouxel as CFO of Evotec, and updates from Elekta, Forx, Abzena and more
BioCentury | Feb 5, 2025
Management Tracks
Management changes at Astellas
Plus: Lundbeck board planning to elect Dorothea Wenzel chair, and updates from PacBio and Uvax Bio
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Jan 3, 2025
Product Development
Axsome to lean on totality of data in Alzheimer’s agitation submission
Company looks to expand the label of depression drug AXS-05, while bringing Alzheimer’s agitation its second mechanism
BioCentury | Nov 6, 2024
Product Development
Two upcoming readouts could shape the market for κ-opioid antidepressants
Emerging class could find niche among patients whose major depressive disorder includes symptoms of anhedonia
BioCentury | Oct 19, 2024
Finance
Cash raises for Inventiva, Akeso, Capricor
Public Equity Report: French biotech to fund MASH study with €348M lifeline; bispecifics developer raises $250; DMD cardiomyopathy play prices follow-on
BioCentury | Oct 15, 2024
Deals
Three new partnerships that could be worth over $1B
Deals report: Astellas-AviadoBio in CNS gene therapy deal, Merck-Mestag to identify inflammatory targets, Eli Lilly-KeyBioscience tackling obesity
BioCentury | Oct 15, 2024
Product Development
Causal biology & big data, ultrarare drugs at FDA, and more: a BioCentury podcast
Identifying causal biology in an age of big data — where to start? Plus: latest in Stealth’s bid to get ultrarare drug through FDA, and Lundbeck buys Longboard
Items per page:
1 - 10 of 891